Experienced healthcare professional with over 25 years achieving transformational results through the leadership of both business and scientific teams in big pharma groups such as Merck, Bristol-Myers Squibb and Aché Laboratories in Brazil. At Knight, Mr. Saverio has been instrumental to strengthening company’s portfolio through licensing and acquisition of new products, which has been expanding Knight’s presence across different therapeutic areas and geographies. Mr. Saverio is an innovative business executive with a track record of leading hundreds of deals and R&D programs, which resulted in the launch of 300+ products in several markets worldwide, as well as acquisitions and out-licensing deals valued at over US$ 500 million. In addition, Mr. Saverio serves on the board of Nintx Therapeutics. Mr. Saverio holds a degree in Pharmacy and Biochemistry, and an MBA from the University of Sao Paulo (FIA/USP).Mr. Saverio is based in São Paulo, Brazil.

Head of the Innovation Center which integrates all areas related to Research and Development, including technical, clinical and business development. Leader of a very skilled and engaged team (300+). Onco CMO Structuring. Nanotech venture creation with a European Company. 200+ products launched or added to the company's pipeline during this period. Leader of successful M&A and out-licensing deals valued at US$ 400+ MM.

Head of all company's business development activities, including in-licensing and out-licensing deals, exports, alliance managment and organic new product development programs. 60+ new products launched or added to the company's pipeline during this period. Successful conclusion of out-licensing deals enabling the launch of innovative products in Latin America, Asia, Africa and Europe.

Responsible for the inclusion of approximately 50 products in the companies pipeline from in-licensing deals or internal developments that were afterwards launched in Brazil and some other territories. Development of a robust process to portfolio renewal, including the creation of medical scientific boards and ideation models involving more than 20 areas in the company.